IMDX
Insight Molecular Diagnostics Inc.·Healthcare
6.41
0.466%(−0.03)
Close PriceLast Updated: — ET
52W L: $2.3352W H: $8.51
IMDX NEWS
seekingalpha.com
May 13
Insight Molecular Diagnostics Inc. (IMDX) Q1 2026 Earnings Call Transcript
Insight Molecular Diagnostics Inc. (IMDX) Q1 2026 Earnings Call Transcript
globenewswire.com
May 13
IMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure Commercialization
Progressing toward commercialization with third-party head-to-head data publications and GALACTIC registry study engagement Northeast kidney transplant center (among the top 10 in the U.S.) is first to sign clinical trial agreement to participate in GALACTIC study Booked research-use-only purchase by E.U. transplant center and APAC purchase expected in coming days Anticipate significant U.S. orders to follow FDA marketing authorization Encouraging dialogue with FDA supports expected authorization later in 2026 NASHVILLE, Tenn.
globenewswire.com
Apr 14
Real-World Evidence and Industry Momentum Builds for iMDx's Flagship GraftAssure Assay
Positive real-world head-to-head data on GraftAssureTM assay to be presented at the 39th European Immunogenetics and Histocompatibility Conference (EFI2026), April 21–24, 2026 in Edinburgh, Scotland Three posters to be presented at the 63rd European Renal Association (ERA) Congress, June 3–6, 2026 in Glasgow, Scotland Favorable real-world evidence poster to be presented at the American Transplant Congress (ATC), June 20–24, 2026 in Boston Unaudited first quarter 2026 cash balance of $29.4 million is in line with year-end and Q4 2025 conference call guidance Company to host fireside chat and one-on-one meetings with investors at Needham Virtual Healthcare Conference on Wednesday, April 15th NASHVILLE, Tenn., April 14, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that its industry conference schedule this spring will highlight new independent clinical data supporting its GraftAssureTM technology and support continued commercial and clinical engagement with the global transplant community.
seekingalpha.com
Mar 26
Insight Molecular Diagnostics Inc. (IMDX) Q4 2025 Earnings Call Transcript
Insight Molecular Diagnostics Inc. (IMDX) Q4 2025 Earnings Call Transcript
globenewswire.com
Mar 26
IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results
NASHVILLE, Tenn., March 26, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its fourth quarter results:
globenewswire.com
Mar 20
iMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare Conference
NASHVILLE, Tenn., March 20, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report fourth quarter 2025 financial results after the market closes on Thursday, March 26, 2026.
